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In our case, a 45-year-old male patient had multiple fractures accompanied by hypophosphatemia. FGF-23 levels were significantly
increased, and total body magnetic resonance imaging (MRI) revealed a tumor mass located at the distal tibia leading to the
diagnosis of tumor-induced osteomalacia (TIO). After resection of the tumor, hypophosphatemia and the increased levels of FGF-
23 normalized within a few days. Subsequentmicroscopic examination and immunohistochemical analysis revealed a phosphaturic
mesenchymal tumor mixed connective tissue variant (PMTMCT) showing a positive expression of somatostatin receptor 2A
(SSTR2A), CD68, and Periostin. Electron microscopy demonstrated a poorly differentiated mesenchymal tumor with a multifocal
giant cell component and evidence of neurosecretory-granules. However, the resected margins showed no tumor-free tissue, and
therefore a subsequent postoperative radiotherapy was performed. The patient is still in complete remission after 34 months.
Tumor resection of PMTMCTs is the therapy of choice. Subsequent radiotherapy in case of incompletely resected tumors can be an
important option to avoid recurrence or metastasis even though this occurs rarely. The prognostic value of expression of Periostin
has to be evaluated more precisely in a larger series of patients with TIO.
1. Introduction
Tumor-induced osteomalacia (TIO) is a rare, acquired para-
neoplastic disorder characterized by a renal phosphate leak
leading to hypophosphatemia and deranged bone turnover.
The typical biochemical pattern of TIO includes normal cir-
culating levels of calcium and parathormone (PTH), normal
or low levels of 1.25-dihydroxyvitamin D (1.25-(OH)
2
D), and
elevated levels of alkaline phosphatase [1–6]. The renal phos-
phate leak manifests itself in hypophosphatemia. Typically,
patients with TIO complain of progressive musculoskeletal
pain and muscle weakness. During the diagnostic procedure
fractures in various localizations are found frequently. The
cause of TIO are usually small, slowly growing tumors
of mesenchymal origin (phosphaturic mesenchymal tumor
mixed connective tissue variant (PMTMCT) [5, 7–10].
In TIO most tumors overexpress the protein fibroblast
growth factor-23 (FGF-23) inhibiting renal phosphate reab-
sorption in the proximal tubules and acting as a phosphaturic
factor [1, 3, 11]. In these cases, FGFR-23 levels are increased
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and immunohistochemical analysis of the tumor is positive
[1, 3, 11]. The primary transport protein responsible for
phosphate reabsorption in the kidney is the type II sodium-
phosphate cotransporter (NPT2a) localized in the proximal
tubule. High circulating FGF-23 levels produce renal phos-
phate wasting through the downregulation of NPT2a [2, 3, 9].
Matrix extracellular phosphoglycoprotein (MEPE) [12] and
frizzled related protein-4 (FRP-4) have emerged as candidate
mediators of the bone-renal pathophysiology as well but are
rarely described in literature, so far [11, 12].
Diagnosis of TIO is often extremely difficult since tumors
can be too small for detection by conventional radiologi-
cal methods. High-resolution magnetic resonance imaging
(MRI) of the whole body is the currently proposed method
of choice to confirm the location of the tumor. F-18 fluo-
rodeoxyglucose positron emission tomography (FDG-PET)
is a very sensitivemethod [9, 10, 13] but also nonspecific.Mes-
enchymal tumors often express somatostatin receptors [14];
therefore, octreotide scintigraphy is another functional imag-
ing modality. In recent literature, Gallium Dotatate PET has
emerged as a virtually ideal investigation to localize tumors
causing TIO as well and performed better than F-FDG
PET/CT in some studies and seems to be a promising diag-
nostic tool in patients in whom 111In-octreotide SPECT/CT
prior failed to detect a tumor [15, 16]. Further studies with
larger patient population are warranted to validate the data.
In rare cases, a venous sampling of FGF-23 is necessary to
detect the tumor [9, 17]. For tumors that cannot be located,
medical treatment with phosphate supplements and active
vitamin D (calcitriol or alpha calcitriol) is a therapeutic
option [9].
If the responsible neoplasm is surgically removed, the
abnormalities in phosphate wasting and in vitamin Dmetab-
olism typically dissolve in a few days.
2. Materials and Methods
The described patient has given written consent for publica-
tion of the data and the photographs of the histopathology
of the tumor. The following antibodies were used for the
immunohistochemical analysis performed at the Institute
for Surgical Pathology in Zurich: somatostatin receptor 2A
(SSTR2A), polyclonal antibody, dilution 1 : 100, Zytomed
Systems; OSF-2/Periostin, monoclonal antibody, dilution
1 : 1000, R&D Systems; CD 68, monoclonal antibody, dilution
1 : 50, DAKO A/S. Human FGF-23 c-terminal was measured
in the laboratories of SynlabWeiden, Germany. An ELISA kit
of the Company, Immutopics, Inc., was used.
3. Case Report
A 45-year-old man was admitted to our tertiary Rheuma-
tology center due to acute aggravation of systemic bone
pain. The symptoms (pain predominantly in knees, heels,
and costosternal joints) worsened gradually during the last
weeks but had developed one year previously. The patient
had a medical history of hypertension and denied any family
history of metabolic bone disease.
Upon physical examination (weight: 96 kg, height:
173 cm, and BMI: 32 kg/m2), only painful knees and heels
without swelling were conspicuous. Laboratory data are
shown in Table 1. A 24-hour urine sample revealed an
increased phosphate clearance of 44.7mL/min (normal
range: 5–16mL/min). Fractional excretion of phosphate was
increased with 19.2% (normal range: <5% in the setting of
hypophosphatemia). Radiological images revealed beginning
degenerative signs. A 700MBq technetium-Teceos bone scan
demonstrated increased uptake in the proximal right tibia
and fibula, the right calcaneus, the ventral ribs, and both
femoral necks. An MRI of the right knee and right calcaneus
showed several months old fracture of the proximal tibia and
a capillary fracture of the calcaneus.
The dual energy X-ray absorptiometry (DXA) scan
showed a low mineral density (Z-score of the lumbar spine:
−1.4; Z-score of the femoral neck: −1.5). A bone biopsy of the
proximal tibia revealed no signs for fibrosis, osteomalacia, a
neoplasm, or a Morbus Paget.
Based on the differential diagnosis of a TIO, an MRI of
the whole body was performed revealing a tumor, measuring
5.2 × 2.2 × 1.5 cm in size, located at the right dorsal distal
tibia. On T1-weighted images the tumor showed isointensity
with themuscle tissue, onT2-weighted images hyperintensity
(Figure 1(a)). Complementary, an examination with ultra-
sound was performed showing a tumor of low echogenicity
(Figure 1(b)).
The diagnosis of primary TIO was confirmed without
evidence of a secondary TIO (PSA in normal range, incon-
spicuous CT scan of the lung). Consequently, a tumor exci-
sion was performed in the Department of Trauma Surgery,
University of Regensburg. Before the operation the level of
human FGF-23 c-terminal was 0.545 RU/mL (normal range:
0.026–0.110 RU/mL).The level of 1.25-(OH)
2
Dwas decreased
to 2.5 pg/mL despite substitution. The patient still showed
hypophosphatemia with a level of 1.83mg/dL despite oral
substitution.
The histopathology of the resected tissue revealed a
PMTMCT, measuring 5 × 2 × 1.5 cm in size. The tumor
consisted of monomorphic cells with round cell nuclei with-
out increased mitotic activity (MIB 1 < 2%) and scattered
giant cells in small groups without signs of malignancy
(Figures 2(a) and 2(b)).The tumor showednonecrosis and no
calcification. The histopathology in context with the clinical
findings is suitable for a PMTMC. However, the resected
margins showed no tumor-free tissue. The immunohisto-
chemical staining revealed a positive expression of SSTR2A,
CD68, and POSTN (OSF-2/Periostin) (Figures 2(c)–2(e)).
Complementarily, an electron microscopy investigation was
performed revealing an admixture of spindle to pleomorphic
shaped cells with deep indentations of the nuclear membrane
and scant cell organella in the cytoplasm. The cells displayed
some short RER profiles, few mitochondria, dispersed cyto-
plasmic filaments of intermediate type; in some of them
singular inclusions resembling neurosecretory granules were
found (Figures 3(a) and 3(b)).Thesemembrane-bound struc-
tures had a diameter of approximately 200 nm and some-
times a hardly visible “dense core” could be recognized
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Table 1: Laboratory data of the patient before and after resection of the giant cell tumor.
Laboratory value















0.396 (+) 0.037 (normal) Normal Normal Normal Normal
Phosphate
(2.6–4.5mg/dL) 1.95 (−) n.p. Normal Normal 2.14 (−) Normal
Calcium
(8.5–10.1mg/dL) Normal Normal Normal Normal Normal Normal
Alkaline phosphatase
(40–129U/L) 305U/L 276U/L 178U/L Normal Normal Normal
Bone specific alkaline
phosphatase (<75%) 79.6% n.p. n.p. n.p. Normal Normal
1.25-(OH)2D
(16–81 pg/mL) 4.83 (−) n.p. Normal Normal Normal Normal
25-(OH)-D
(20–60 ng/mL) 21 (normal) n.p. 17.3 (−) Normal Normal Normal
Parathyroid hormone
(15–65 ng/L) Normal Normal Normal Normal Normal Normal
n.p. = not performed.
(a) (b)
Figure 1: (a) MRI of the giant cell tumor at the distal tibia and (b) an ultrasound examination of the tumor.
(primarily formalin fixed material). These cells were densely
dispersed in a collagen rich matrix with numerous small
blood vessels—most of them without a formed lumen. In
the matrix diffuse dispersed mast cells and singular giant
cells (some multinuclear) with a histiocytic phenotype were
found. Some of the giant cells contained vesicular structures
with pericentric located dense granules resembling secretory
inclusions similar to those observed in, for example, insuli-
noma (Figure 3(c)). Singular giant cells showed randomly
oriented sarcomeric structures (Figure 3(d)).
Since the tumor was not resected totally, radiotherapy of
the right lower extremity has subsequently been performed,
as a relapse of a benign giant cell tumor, or PMTMCT has
been described [2, 9, 18, 19]. The case was discussed contro-
versially in our interdisciplinary conference of tumors
because metastasis in PMTMCTs is rarely described. Because
of low toxicity (relatively small clinical target volume (CTV)
for irradiation and large space to critical organs of risk) the
decision came to perform radiotherapy to avoid the risk of
later recurrence ormetastasis. In case of recurrence a reresec-
tion could most likely have led to distinct loss of function of
the limb. Including image fused CT- andMRI-scans for treat-
ment planning, theCTV consisted of thewhole compartment
including bone structures of the lower extremity. The radio-
therapy was performed with a daily dosage of 1.8 Gy (6 and
15MV photons) five times a week until a cumulative dose of
45Gy (acute side effects: radiodermatitis CTC grade I).
Two days after resection of the tumor, the level of FGF-
23 c-terminal was within the normal range (0.037 RU/mL,
normal range: 0.026–0.110 RU/mL) and treatment with phos-
phate was stopped. The level of alkaline phosphatase was
still elevated at 276U/L. The patient reported a significant
improvement of his pain in the knees and heels allowing
almost complete reduction of analgesics.
Two months later, laboratory data showed normal
levels for phosphate, calcium, and FGF-23 c-terminal
(0.054 RU/mL). The alkaline phosphatase was still elevated
at 178U/L; the level of 25-(OH)-D was decreased with
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(a) (b)
(c) (d) (e)
Figure 2: Phosphaturic mesenchymal tumor mixed connective tissue variant. (a) Histopathology of the tumor consisting of monomorphic
cells with round cell nuclei without increased mitotic activity (hematoxylin-eosin stain: HE 200x), (b) scattered multinucleated giant cells
(HE 400x), and ((c)–(e)) expression of CD68, SSTR2, and POSTN in tumor tissue (immunohistochemistry).
17.3 ng/mL; the level of 1.25-(OH)-D was normal. An MRI
performed on the tibia showed no relapse of the giant cell
tumor.
There was a follow-up visit 26, 29, and 34 months after
establishment of diagnosis. The follow-up data including
laboratory results and DXA has been performed again and
showed normal levels of FGF-23 c-terminal and vitamin D
(see Table 1) and a normal mineral density of bone. The level
of phosphate was slightly decreased with 2.14mg/dL, and an
oral substitution was restarted.The level of phosphate turned
to normal at last follow-up. An MRI of the tibia showed no
relapse. Due to disease remission, additional radiographic
investigations were not performed.
4. Discussion
This case report presents a patient with a PMTMCT leading
to the rare disease TIO.
The histopathology of tumors leading to TIO reveals in
70–80% of cases PMTMCTs [2] which are rare neoplasms
occurring in approximately 53%of cases within bones, in 45%
in soft tissue and in 3% of patients in the skin. PMTMCT is
normally benign, but malignant variants have already been
described [2, 19, 20].
Folpe and colleagues [19] performed a series of immuno-
histochemical staining in tumors leading to TIO.They found
a positive staining for FGF-23 in about 70% of all cases;
all other markers remained negative. FGF-23 overexpression
produced predominantly in bone suppresses osteoblast dif-
ferentiation as well as matrix mineralization, which suggests
that FGF-23 acts directly on bone by reducing mineralization
[12]. Furthermore, somatostatin receptors have been found
to be present in many TIO tumors [14, 17, 21]. Houang et al.
showed in all 15 tumors of 14 patients with TIO a positive
staining for FGF-23 and SSTR2A. They concluded that a
positive staining for both markers is highly sensitive to
PMTs, but not specific. A negative staining can serve as an
excellent rule-out test for this diagnosis [21]. In our case,
the immunohistochemical staining for SSTR2A, CD 68, and
Periostin was positive (Figures 2(c)–2(e)); the staining for
FGF-23 could not be established. However, given that FGF-
23 serum levels normalized after resection it is clear that the
tumor must have produced FGF-23.
To our knowledge a positive staining of Periostin of PMTs
of patients with TIO has so far not been described in the liter-
ature. Periostin is a newly identified mediator of the inflam-
matory process and seems to play a role in collagen fibroge-
nesis and tumor development. It is an extracellular matrix
protein expressed by fibroblasts and has been observed in a
variety of human malignancies predicting a poor prognosis
[22–25]. Several studies revealed that Periostin is upregulated
in a wide variety of cancers such as colon, pancreatic,
ovarian, breast, non-small cell lung, and head and neck
cancer [26, 27]. Periostin binding to the integrins activates
the Akt/PKB- and FAK-mediated signaling pathways which
lead to increased cell survival, angiogenesis, invasion, and
epithelial-mesenchymal transition of carcinoma cells [24, 27].
Furthermore Periostin expression is upregulated and associ-
atedwithmyocardial fibrosis in patientswith heart failure and
seems to play a role in various inflammatory settings [28]. In
patients with non-small cell lung cancer (NSCLC) a positive
immunostaining of Periostin in the mesenchymal areas, but
not in the cancer cells themselves, could be demonstrated.
The patients with tumors exhibiting high-level Periostin
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(c) (d)
Figure 3: Primary formalin fixed tumor tissue and electron microscopic images. (a) Ultrastructural features of spindle shaped stromal
cells with organelle-poor cytoplasm and few dense granules (arrow). Orig. mag. × 3125. (b) The granules resemble neurosecretory granules,
diameter approx. 200 nm (not typical “dense core” granules), orig. mag. × 10,000. (c) Rounded tumor cell with a nuclear indentation, scant
organella, and any cell surface specialized structures. Note singular electron dense granules in cytoplasm (arrows). Orig. mag. × 4,000. (d)
Ultrastructural aspect of a giant multinuclear cell displaying in the organelle-rich cytoplasm some vesicular structures with pericentric dense
inclusions (arrows). Orig. mag. × 3125.
expression showed a significantly shorter survival time [22].
The results of Hong et al. showed that the overexpression
of Periostin predicts a poor prognosis; therefore the authors
conclude that overexpression of Periostin could be regarded
as a novel molecule in the progression and development
of NSCLC. Further studies have to follow to evaluate the
role of Periostin expression in patients with TIO. Periostin
upregulation might be an indirect marker for a higher risk
of recurrence or development of metastasis. The positive
expression of Periostin supports the option of subsequent
postoperative radiotherapy in incompletely resected tumors.
In terms of ultrastructural features, neurosecretory gran-
ules were found similar to a neuroendocrine tumor [9, 29–
31]. However, in these studies immunostaining for typical
markers of neurosecretory tumors was negative.
In our case report, the electron microscopy investigation
showed ultrastructural features of spindle shaped stromal
cells with organelle-poor cytoplasm and a few dense granules
resembling neurosecretory granules. These findings are con-
sistent with the majority of the literature [29–31]. However,
some PMTs do not show neurosecretory granules [32].
Electron microscopy is a helpful complementary diagnostic
tool in ambiguous histopathology.
Late recurrence due to metastatic disease is rare but
possible, occurring in less than 5%of the patientswithTIO [9,
19, 33]. A small subset of apparently benign giant cell tumors
develops hematogenous metastases, usually of the lung [34].
Because of the positive margins of the resected tissue in our
patient a subsequent radiotherapy was initiated. The case
was discussed controversially in our interdisciplinary confer-
ence of tumors because metastasis in PMTMCTs is rarely
described. Because of low toxicity (see page 6) the decision
came to perform radiotherapy to avoid the risk of later recur-
rence or metastasis because of incompletely resected margins
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of the tumor. Furthermore, in case of recurrence a reresection
could most likely have led to distinct loss of function of the
limb. Further studies are needed in patientswith incompletely
resected tumors to determine the postoperative treatment
options.
Caudell and colleagues [18] performed a retrospective
analysis of 25 consecutive patients with giant cell tumors
undergoing radiotherapy adjuvant to surgery, or as an alter-
native treatment in unresectable cases. When radiotherapy is
used for primary treatment, the rate of local control seems
to be satisfactory, whereas patients treated with radiotherapy
for recurrent tumors had worse outcomes [18]. Incompletely
resected giant cell tumors or lesions that are surgically inac-
cessible are usually treated with moderate-dose radiotherapy
(45–50Gy) and have a 65% to 90% likelihood of being locally
controlled [35]. No severe acute or chronic toxicity has been
reported following radiotherapy [34–37].
In conclusion, TIO is a paraneoplastic syndrome caused
by the phosphaturic hormone FGF-23 that can be cured
by removing the responsible neoplasm. Subsequent radio-
therapy in case of incompletely resected tumors can be an
important option to avoid recurrence or metastasis even
though this occurs rarely. Especially if a recurrence with
the need of re-resection would lead to distinct function
of a limb an additive radiotherapy in case of incompletely
resected tumors can be recommended. The prognostic value
of expression of Periostin has to be evaluated more precisely
in a larger series of patients with TIO.
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